Taking the 20-HETE out of the cardiovascular system: the potential of 20-HETE synthesis inhibitors.
In addition to being metabolized by cyclooxygenase and lipooxygenase to prostaglandins and leukotrienes, arachidonic acid can be metabolized to 20-hydroxyeicosatetraenoic acid (20-HETE) by cytochrome P450 enzymes omega-hydroxylases. As 20-HETE has both pro-hypertensive and antihypertensive actions, inhibitors of 20-HETE synthase may not be useful as antihypertensives in all forms of hypertension. However, 20-HETE synthase inhibitors can have cardioprotective and cerebroprotective effects in animal models, and can inhibit angiogenesis; therefore they may have clinical potential in these areas.
Doggrell
Sheila A
SA
Division of Health Practice, Auckland University of Technology-Akoranga Campus, Auckland, New Zealand. s.doggrell@xtra.co.nz
D000578:Amidines / Q000627:therapeutic use; D020533:Angiogenesis Inhibitors / Q000627:therapeutic use; D000818:Animals; D002560:Cerebrovascular Circulation / Q000187:drug effects*; D004791:Enzyme Inhibitors / Q000627:therapeutic use*; D006801:Humans; D006893:Hydroxyeicosatetraenoic Acids / Q000037:antagonists & inhibitors* / Q000502:physiology; D006973:Hypertension / Q000188:drug therapy*; D015428:Myocardial Reperfusion Injury / Q000517:prevention & control*; D016376:Oligonucleotides, Antisense / Q000627:therapeutic use
D000578:Amidines; D020533:Angiogenesis Inhibitors; D004791:Enzyme Inhibitors; C000708209:HET0016; D006893:Hydroxyeicosatetraenoic Acids; D016376:Oligonucleotides, Antisense; C055987:20-hydroxy-5,8,11,14-eicosatetraenoic acid